These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 27678173)

  • 1. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems.
    Bangde P; Atale S; Dey A; Pandit A; Dandekar P; Jain R
    Curr Gene Ther; 2017; 17(2):170-183. PubMed ID: 28494742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
    Meng J; Agrahari V; Youm I
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
    Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
    Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Nanomedicine to the CNS Diseases.
    Carradori D; Gaudin A; Brambilla D; Andrieux K
    Int Rev Neurobiol; 2016; 130():73-113. PubMed ID: 27678175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
    Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
    Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.
    Alajangi HK; Kaur M; Sharma A; Rana S; Thakur S; Chatterjee M; Singla N; Jaiswal PK; Singh G; Barnwal RP
    Mol Brain; 2022 Jun; 15(1):49. PubMed ID: 35650613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-based nanocarriers for CNS-targeted drug delivery.
    Micheli MR; Bova R; Magini A; Polidoro M; Emiliani C
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):71-86. PubMed ID: 22283231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
    Goyal K; Koul V; Singh Y; Anand A
    Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.
    DeMarino C; Schwab A; Pleet M; Mathiesen A; Friedman J; El-Hage N; Kashanchi F
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):31-50. PubMed ID: 27372507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
    Al-Ahmady ZS
    Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of neurodegenerative disorders employing nanoparticles.
    Spuch C; Saida O; Navarro C
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendrimer advances for the central nervous system delivery of therapeutics.
    Xu L; Zhang H; Wu Y
    ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.